go back

Brexucabtagene Autoleucel (Tecartus)

Rhode Island rates for HCPCS C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $398,107 · 10th–90th $398,107$416,8690%50%90th$398,107Professionalmedian $407,380 · 10th–90th $407,380$407,3800%50%100%$407,380

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
BCBS
Setting
Facility
Modifier
Global
Typical Low
$398,107.17
Median
$398,107.17
Typical High
$416,869.38
BCBS
Setting
Professional
Modifier
Global
Typical Low
$407,380.28
Median
$407,380.28
Typical High
$407,380.28